JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

Timeline

Start

2026-01-20

Primary completion

2028-12-31

Completion

2028-12-31

Drugs

Indications